➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Moodys
McKesson
McKinsey

Last Updated: December 1, 2020

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca LP v. Mylan Pharmaceuticals Inc. (D. Del. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

AstraZeneca LP v. Mylan Pharmaceuticals Inc. (D. Del. 2015)

Docket   Start Trial Date Filed 2015-10-30
Court District Court, D. Delaware Date Terminated 2018-11-29
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties HEC PHARM CO. LTD.; HEC PHARM GROUP; HEC PHARM USA; SANDOZ INC.; SIGMAPHARM LABORATORIES, LLC
Patents 6,251,091; 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934; RE46,276
Attorneys Bradley Roush; HEC Pharm Co. Ltd.; John C. Phillips , Jr.; Liane M. Peterson; Lynne Terrebonne; Megan C. Haney; Michael P. Hogan; Patrick C. Kilgore; Pei-Ru Wey; R. Touhey Myer; Ramy E. Hanna; Richard D. Kirk; Robert S. Silver; Salvatore Guerriero; Sara E. Bussiere; Stephen B. Brauerman; Tara M. Raghavan; Vanessa Ribeiro Tiradentes; William A. Rakoczy
Firms Bayard, P.A.; Caesar Rivise, PC; Foley & Lardner LLP; Gould & Ratner LLP; Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in AstraZeneca LP v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for AstraZeneca LP v. Mylan Pharmaceuticals Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-10-30 1 Complaint AstraZeneca’s U.S. Patent Nos. 6,251,910 (“the ’910 patent”), 6,525,060 (“the ’060 patent”), 7,250,419 (… (“the ’419 patent”), 7,265,124 (“the ’124 patent”), and 8,425,934 (“the ’934 patent”) ME1 21394971v… This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 21. On June 26, 2001, the U.S. Patent and Trademark Office…copy of the ’910 patent is attached hereto as Exhibit A. The claims of the ’910 patent are valid and enforceable External link to document
2016-09-06 129 Redacted Document .S. Patent Nos. 7,265,124 ("'124 Patent") and 8,425,934 ("'934 Patent"…July 20, 2015, HEC Pharm Co., Ltd. filed a Patent Certification with ANDA No. 208508, certifying …quot;) (collectively, "Patents-in-Suit") are invalid, unenforceable or will not be infringed…"; D.I. 1), asserting infringement of the Patents-in-Suit under 35 U.S.C. § 271(e)(2)(A); …, asserting affirmative defenses regarding the Patents-in-Suit, as well as counterclaims for declaratory External link to document
2017-02-20 165 Memorandum Opinion of multiple terms in U.S. Patent Nos. 6,525,060 ("the '060 patent") and 7,265,124 ("…construction for multiple terms in U.S. Patent Nos. 6,525,060 and 7,265,124. Signed by Judge Richard G…as U.S. Patent No. RE46,276 ("the '276 patent"). The '060 and '276 patents share …infringe five of AstraZeneca's patents. (D.I. 1). 2 The patents-in-suit claim chemical compounds as…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which External link to document
2017-02-24 168 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 7,250,419; 7,265,124… 29 November 2018 1:15-cv-01000 830 Patent None District Court, D. Delaware External link to document
2017-03-15 172 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,250,419; 7,265,124; RE 46,276… 29 November 2018 1:15-cv-01000 830 Patent None District Court, D. Delaware External link to document
2017-03-15 174 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 7,250,419; 7,265,124… 29 November 2018 1:15-cv-01000 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.